Molecular Pathologists Propose Third-Party Review Of High-Risk Dx In Alternative To FDA LDT Plan
This article was originally published in The Gray Sheet
Executive Summary
The Association for Molecular Pathology wants a Senate panel to consider a legislative alternative to FDA’s proposed lab developed test (LDT) framework, a plan to modernize the Clinical Laboratory Improvement Amendments Act and let CMS or a third party assess high-risk LDT procedures for clinical validity.
You may also be interested in...
Sen. Alexander Wants To ‘Start From Scratch’ In Regulating Lab-Developed Tests
Senate HELP Committee Chair Lamar Alexander, R-Tenn., suggested he would prefer to “start from scratch” in developing appropriate regulatory controls for laboratory-developed tests, despite a proposed regulatory framework for US FDA for the tests that was more than a decade in the making. That triggered some debate at a Sept. 20 committee hearing.
Patient, Consumer Groups Press For More Oversight Of Device Iterations
Patient and consumer groups urged better FDA control over modifications to marketed products and expressed support for agency oversight of laboratory-developed tests at a recent update meeting on device user fee reauthorization.
House Diagnostics Reg Reform Draft Proposes Pathways For Relaxed Scrutiny
A House Subcommittee plans to take up draft legislation at a hearing next month that brings together test kits and lab-developed tests into a new regulatory category. The proposal offers many ways for tests to avoid a “high-risk” classification. “The Gray Sheet” compares the provisions to recent proposals vetted in the Senate.